Patterns of paediatric massive blood transfusion protocol use in trauma and non-trauma patients.
abnormalities
blood component transfusion
blood transfusion
congenital diseases
hereditary diseases
injuries
neonatal diseases
paediatrics
Journal
Transfusion medicine (Oxford, England)
ISSN: 1365-3148
Titre abrégé: Transfus Med
Pays: England
ID NLM: 9301182
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
19
08
2021
received:
08
02
2021
accepted:
11
10
2021
pubmed:
28
10
2021
medline:
18
1
2022
entrez:
27
10
2021
Statut:
ppublish
Résumé
Massive blood transfusion is infrequently required by children but can be a lifesaving intervention for haemorrhage or coagulopathy. Product volumes and ratios administered during the initiation of paediatric massive blood transfusion protocol (MBTP) are highly variable and the optimal component ratio is unknown. We performed a single-centre retrospective chart review of patients (<20 years) who received MBTP activation from August 2012 through January 2018. Logistic regression was used to determine the association between MBTP use characteristics (including blood product type and volume transfused, extracorporeal membrane oxygenation [ECMO] support, and cardiac arrest occurrence) and 24-h mortality. "Low" product ratio was defined as a ratio of plasma or platelets to red blood cells (RBCs) of <1:2 and "high" as ≥1:2. Ninety-eight MBTPs were activated for 89 patients (range 1-4 per patient). The most common underlying diagnoses were congenital heart disease (CHD, n = 28, 31.5%), followed by cardiopulmonary disease, and trauma. CHD patients required the greatest volume of RBCs (226.3 ml/kg, 95%CI [160.0, 292.7], p = 0.002) and platelets (46.7 ml/kg, 95%CI [33.2, 60.2], p < 0.001). A "low" product ratio was more common for the MBTP, with its incidence similar among the underlying diagnoses. An MBTP developed for trauma patients can be applied to non-trauma patients but standard MBTP components may not be optimal for all children. These findings show that underlying patient diagnoses may be a factor when designing an MBTP for a heterogeneous paediatric population.
Sections du résumé
BACKGROUND
BACKGROUND
Massive blood transfusion is infrequently required by children but can be a lifesaving intervention for haemorrhage or coagulopathy. Product volumes and ratios administered during the initiation of paediatric massive blood transfusion protocol (MBTP) are highly variable and the optimal component ratio is unknown.
METHODS/MATERIALS
METHODS
We performed a single-centre retrospective chart review of patients (<20 years) who received MBTP activation from August 2012 through January 2018. Logistic regression was used to determine the association between MBTP use characteristics (including blood product type and volume transfused, extracorporeal membrane oxygenation [ECMO] support, and cardiac arrest occurrence) and 24-h mortality. "Low" product ratio was defined as a ratio of plasma or platelets to red blood cells (RBCs) of <1:2 and "high" as ≥1:2.
RESULTS
RESULTS
Ninety-eight MBTPs were activated for 89 patients (range 1-4 per patient). The most common underlying diagnoses were congenital heart disease (CHD, n = 28, 31.5%), followed by cardiopulmonary disease, and trauma. CHD patients required the greatest volume of RBCs (226.3 ml/kg, 95%CI [160.0, 292.7], p = 0.002) and platelets (46.7 ml/kg, 95%CI [33.2, 60.2], p < 0.001). A "low" product ratio was more common for the MBTP, with its incidence similar among the underlying diagnoses.
CONCLUSION
CONCLUSIONS
An MBTP developed for trauma patients can be applied to non-trauma patients but standard MBTP components may not be optimal for all children. These findings show that underlying patient diagnoses may be a factor when designing an MBTP for a heterogeneous paediatric population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
439-446Informations de copyright
© 2021 British Blood Transfusion Society.
Références
Parker RI. Transfusion in critically ill children: indications, risks, and challenges. Crit Care Med. 2014;42(3):675-690. https://doi.org/10.1097/CCM.0000000000000176
Karam O, Tucci M. Massive transfusion in children. Transfus Med Rev. 2016;30(4):213-216.
Trauma Quality Improvement Program. ACS TQIP massive transfusion in trauma guidelines. American College of Surgeons, Committee on Trauma; 2014. https://www.facs.org/-/media/files/quality-programs/trauma/tqip/transfusion_guildelines.ashx. Accessed May 22, 2020.
Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007;63(4):805-813. https://doi.org/10.1097/TA.0b013e3181271ba3
Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482. https://doi.org/10.1001/jama.2015.12
Maw G, Furyk C. Pediatric massive transfusion: a systematic review. Pediatr Emerg Care. 2018;34(8):594-598. https://doi.org/10.1097/PEC.0000000000001570
Hendrickson JE, Sha BH, Pereira G, et al. Implementation of a pediatric trauma massive transfusion protocol: one institution's experience. Transfusion. 2012;52:1228-1236. https://doi.org/10.1111/j.1537-2995.2011.03458.x
Evangelista ME, Gaffley M, Neff LP. Massive transfusion protocols for pediatric patients: current perspectives. J Blood Med. 2020;11:163-172. https://doi.org/10.2147/JBM.S205132
Neff LP, Cannon JW, Morrison JJ, Edwards MJ, Spinella PC, Borgman MA. Clearly defining pediatric massive transfusion: cutting through the fog and fiction with combat data. J Trauma Acute Care Surg. 2015;78(1):22-28; discussion 28-29. https://doi.org/10.1097/TA.0000000000000488
American Heart Association. Management of shock. Pediatric Advanced Life Support, Provider Manual. Frist American Heart Association Printing; 2016:197-233.
Goobie SM, Haas T. Bleeding management for pediatric craniotomies and craniofacial surgery. Paediatr Anaesth. 2014;24(7):678-689. https://doi.org/10.1111/pan.12416
Chidester SJ, Williams N, Wang W, Groner JI. A pediatric massive transfusion protocol. J Trauma Acute Care Surg. 2012;73(5):1273-1277. https://doi.org/10.1097/TA.0b013e318265d267
Nosanov L, Inaba K, Okoye O, et al. The impact of blood product ratios in massively transfused pediatric trauma patients. Am J Surg. 2013;206(5):655-660. https://doi.org/10.1016/j.amjsurg.2013.07.009
Diab YA, Wong EC, Luban NL. Massive transfusion in children and neonates. Br J Haematol. 2013;161(1):15-26.
Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14:199-205.
Agency for Healthcare Research and Quality. ICD-10 CCS Category Names (Full Labels) Single-level CCS and Multi-level CCS. Agency for Healthcare Research and Quality; 2017. https://www.hcup-us.ahrq.gov/toolssoftware/ccs10/CCSCategoryNames(FullLabels).pdf. Accessed August 10, 2019.
Bateman ST, Lacroix J, Boven K, et al. Anemia, blood loss, and blood transfusions in north American children in the intensive care unit. Am J Respr Crit Care Med. 2008;178:26-33.
Willems A, Patte P, De Groote F, Van der Linden P. Cyanotic heart disease is an independent predicting factor for fresh frozen plasma and platelet transfusion after cardiac surgery. Transfus Apher Sci. 2019;58:304-309. https://doi.org/10.1016/j.transci.2019.03.014
Davis CS, Milia D, Gottschall JL, Weigelt JA. Massive transfusion associated with a hemolytic transfusion reaction: necessary precautions for prevention. Transfusion. 2019;59(8):2532-2535.
Giancarelli A, Birrer KL, Alban RF, Hobbs BP, Liu-DeRyke X. Hypocalcemia in trauma patients receiving massive transfusion. J Surg Res. 2016;202(1):182-187.
Guerado E, Medina A, Mata MI, Galvan JM, Bertrand ML. Protocols for massive blood transfusion: when and why, and potential complications. Eur J Trauma Emerg Surg. 2016;42(3):283-295.
Delaney M, Stark PC, Suh M, et al. Massive transfusion in cardiac surgery: the impact of blood component ratios on clinical outcomes and survival. Anesth Analg. 2017;124(6):1777-1782. https://doi.org/10.1213/ANE.0000000000001926
Centers for Disease Control. 10 Leading Causes of Death by Age Group, United States, National Center for Injury Prevention and Control. 2018. https://www.cdc.gov/injury/images/lc-charts/leading_causes_of_death_by_age_group_2018_1100w850h.jpg. Accessed May 22, 2020.
Sedhev M, Grigorian A, Kuza C, et al. Comparing unbalanced and balanced ratios of blood products in massive transfusion to pediatric trauma patients: effects on mortality and outcomes. Eur J Trauma Emerg Surg. 2020;1-8. https://doi.org/10.1007/s00068-020-01461-7
Spinella PC. Warm fresh whole blood transfusion for severe hemorrhage: U.S. military and potential civilian applications. Crit Care Med. 2008;36(7):S340-S345. https://doi.org/10.1097/CCM.0b013e31817e2ef9
Leeper CM, Yazer MH, Cladis FP, Saladino R, Triulzi DJ, Gaines BA. Use of uncrossmatched cold-stored whole blood in injured children with hemorrhagic shock. JAMA Pediatr. 2018;172(5):491-492. https://doi.org/10.1001/jamapediatrics.2017.5238
Nellis ME, Saini A, Spinella P, et al. Pediatric plasma and platelet transfusions on extracorporeal membrane oxygenation: a subgroup analysis of two large international point-prevalence studies and the role of local guidelines. Pediatr Crit Care Med. 2020;21(3):267-275. https://doi.org/10.1097/PCC.0000000000002160
Chandler WL, Ferrell C, Trimble S, Moody S. Development of a rapid emergency hemorrhage panel. Transfusion. 2010;50(12):2547-2552.